Daptomycin: A novel cyclic lipopeptide antimicrobial

83Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose. The development, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and dosage and administration of daptomycin are reviewed. Summary. Daptomycin, a novel cyclic lipopeptide antimicrobial, is bactericidal against a range of gram-positive bacteria, including many multiple-drug-resistant isolates. It has only minimal activity against anaerobic bacteria and no activity against gram-negative bacteria. Daptomycin exhibits linear pharmacokinetics, and the plasma concentration-versus-time relationship is best described by a two-compartment model with first-order elimination. The initial bactericidal activity is rapid, extensive, and concentration related. In clinical trials, daptomycin has shown efficacy in treating complicated skin and skin-structure infections (CSSSIs); the drug carries FDA-approved labeling for same. The adverse effects of daptomycin appear comparable to those of vancomycin and semisynthetic penicillins. The dosage for CSSSIs is 4 mg/kg by i.v. infusion every 24 hours. Conclusion. Daptomycin is bactericidal against gram-positive organisms and offers an option in the treatment of CSSSIs. Copyright © 2005, American Society of Health-System Pharmacists, Inc. All rights reserved.

Cite

CITATION STYLE

APA

Schriever, C. A., Fernández, C., Rodvold, K. A., & Danziger, L. H. (2005, June 1). Daptomycin: A novel cyclic lipopeptide antimicrobial. American Journal of Health-System Pharmacy. American Society of Health-Systems Pharmacy. https://doi.org/10.1093/ajhp/62.11.1145

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free